{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:45Z","timestamp":1790746845580,"version":"4.1.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41590-024-01815-y","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T16:03:49Z","timestamp":1714665829000},"page":"743-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The ouroboros of autoimmunity"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-4169","authenticated-orcid":false,"given":"Jean-Laurent","family":"Casanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1894-8882","authenticated-orcid":false,"given":"Jessica","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Donadieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8573-6820","authenticated-orcid":false,"given":"Anna-Lena","family":"Neehus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2603-0323","authenticated-orcid":false,"given":"Anne","family":"Puel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-8437","authenticated-orcid":false,"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"1815_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1074-7613(02)00338-2","volume":"17","author":"RS Liblau","year":"2002","unstructured":"Liblau, R. S., Wong, F. S., Mars, L. T. & Santamaria, P. Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 17, 1\u20136 (2002).","journal-title":"Immunity"},{"key":"1815_CR2","doi-asserted-by":"publisher","first-page":"103356","DOI":"10.1016\/j.autrev.2023.103356","volume":"22","author":"S Sciascia","year":"2023","unstructured":"Sciascia, S. et al. Autoantibodies testing in autoimmunity: diagnostic, prognostic and classification value. Autoimmun. Rev. 22, 103356 (2023).","journal-title":"Autoimmun. Rev."},{"key":"1815_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang, L., Wang, F. S. & Gershwin, M. E. Human autoimmune diseases: a comprehensive update. J. Intern. Med. 278, 369\u2013395 (2015).","journal-title":"J. Intern. Med."},{"key":"1815_CR4","unstructured":"Gershwin, M. E. & Tsokas, G. The Autoimmune Diseases (Academic Press, 2019)."},{"key":"1815_CR5","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1172\/JCI70231","volume":"123","author":"JV Price","year":"2013","unstructured":"Price, J. V. et al. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J. Clin. Invest. 123, 5135\u20135145 (2013).","journal-title":"J. Clin. Invest."},{"key":"1815_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","volume":"15","author":"J Ilonen","year":"2019","unstructured":"Ilonen, J., Lempainen, J. & Veijola, R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol. 15, 635\u2013650 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1815_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMra2033982","volume":"385","author":"S Berentsen","year":"2021","unstructured":"Berentsen, S. & Barcellini, W. Autoimmune hemolytic anemias. N. Engl. J. Med. 385, 1407\u20131419 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21037\/sci.2017.09.07","volume":"4","author":"Y Xiao","year":"2017","unstructured":"Xiao, Y., Zhao, S. & Li, B. Aplastic anemia is related to alterations in T cell receptor signaling. Stem Cell Investig. 4, 85 (2017).","journal-title":"Stem Cell Investig."},{"key":"1815_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/16078454.2019.1642548","volume":"24","author":"L Wang","year":"2019","unstructured":"Wang, L. & Liu, H. Pathogenesis of aplastic anemia. Hematology 24, 559\u2013566 (2019).","journal-title":"Hematology"},{"key":"1815_CR10","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1016\/j.cell.2022.07.004","volume":"185","author":"J-L Casanova","year":"2022","unstructured":"Casanova, J.-L. & Abel, L. From rare disorders of immunity to common determinants of infection: following the mechanistic thread. Cell 185, 3086\u20133103 (2022).","journal-title":"Cell"},{"key":"1815_CR11","doi-asserted-by":"publisher","first-page":"e2301186120","DOI":"10.1073\/pnas.2301186120","volume":"120","author":"J-L Casanova","year":"2003","unstructured":"Casanova, J.-L. From second thoughts on the germ theory to a full-blown host theory. Proc. Natl Acad. Sci. USA 120, e2301186120 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1815_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-3083.1989.tb01204.x","volume":"30","author":"A Fomsgaard","year":"1989","unstructured":"Fomsgaard, A., Svenson, M. & Bendtzen, K. Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand. J. Immunol. 30, 219\u2013223 (1989).","journal-title":"Scand. J. Immunol."},{"key":"1815_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0307-742X(21)00603-2","volume":"11","author":"JB Winfield","year":"1985","unstructured":"Winfield, J. B. Anti-lymphocyte antibodies in systemic lupus erythematosus. Clin. Rheum. Dis. 11, 523\u2013549 (1985).","journal-title":"Clin. Rheum. Dis."},{"key":"1815_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/672126","volume":"2014","author":"C Li","year":"2014","unstructured":"Li, C. et al. Antilymphocyte antibodies in systemic lupus erythematosus: association with disease activity and lymphopenia. J. Immunol. Res. 2014, 672126 (2014).","journal-title":"J. Immunol. Res."},{"key":"1815_CR15","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.4049\/jimmunol.138.6.1750","volume":"138","author":"S Minota","year":"1987","unstructured":"Minota, S. & Winfield, J. B. IgG anti-lymphocyte antibodies in systemic lupus erythematosus react with surface molecules shared by peripheral T cells and a primitive T cell line. J. Immunol. 138, 1750\u20131756 (1987).","journal-title":"J. Immunol."},{"key":"1815_CR16","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young, N. S. Aplastic anemia. N. Engl. J. Med. 379, 1643\u20131656 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJM197510092931505","volume":"293","author":"LA Boxer","year":"1975","unstructured":"Boxer, L. A., Greenberg, M. S., Boxer, G. J. & Stossel, T. P. Autoimmune neutropenia. N. Engl. J. Med. 293, 748\u2013753 (1975).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1056\/NEJM197510092931504","volume":"293","author":"P Lalezari","year":"1975","unstructured":"Lalezari, P., Jiang, A. F., Yegen, L. & Santorineou, M. Chronic autoimmune neutropenia due to anti-NA2 antibody. N. Engl. J. Med. 293, 744\u2013747 (1975).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood.V91.1.181","volume":"91","author":"J Bux","year":"1998","unstructured":"Bux, J., Behrens, G., Jaeger, G. & Welte, K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 91, 181\u2013186 (1998).","journal-title":"Blood"},{"key":"1815_CR20","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/jcp.33.11.1110","volume":"33","author":"C Dresch","year":"1980","unstructured":"Dresch, C., Flandrin, G. & Breton-Gorius, J. Phagocytosis of neutrophil polymorphonuclears by macrophages in human bone marrow: importance in granulopoiesis. J. Clin. Pathol. 33, 1110\u20131113 (1980).","journal-title":"J. Clin. Pathol."},{"key":"1815_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0022-3476(81)80636-1","volume":"98","author":"RT Parmley","year":"1981","unstructured":"Parmley, R. T. et al. Phagocytosis of neutrophils by marrow macrophages in childhood chronic benign neutropenia. J. Pediatr. 98, 207\u2013212 (1981).","journal-title":"J. Pediatr."},{"key":"1815_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood.V14.6.748.748","volume":"14","author":"P Lalezari","year":"1959","unstructured":"Lalezari, P. & Spaet, T. H. Studies on the genetics of leukocyte antigens. Blood 14, 748\u2013758 (1959).","journal-title":"Blood"},{"key":"1815_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood.V15.2.236.236","volume":"15","author":"P Lalezari","year":"1960","unstructured":"Lalezari, P., Nussbaum, M., Gelman, S. & Spaet, T. H. Neonatal neutropenia due to maternal isoimmunization. Blood 15, 236\u2013243 (1960).","journal-title":"Blood"},{"key":"1815_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching, A. R. et al. ANCA-associated vasculitis. Nat. Rev. Dis. Primers 6, 71 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1815_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.smim.2016.03.004","volume":"28","author":"N Thieblemont","year":"2016","unstructured":"Thieblemont, N., Wright, H. L., Edwards, S. W. & Witko-Sarsat, V. Human neutrophils in auto-immunity. Semin. Immunol. 28, 159\u2013173 (2016).","journal-title":"Semin. Immunol."},{"key":"1815_CR26","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/art.41460","volume":"72","author":"Y Zuo","year":"2020","unstructured":"Zuo, Y. et al. Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome. Arthritis Rheumatol. 72, 2130\u20132135 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1815_CR27","doi-asserted-by":"publisher","first-page":"178ra140","DOI":"10.1126\/scitranslmed.3005580","volume":"5","author":"R Khandpur","year":"2013","unstructured":"Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5, 178ra140 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1815_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrrheum.2014.80","volume":"10","author":"HL Wright","year":"2014","unstructured":"Wright, H. L., Moots, R. J. & Edwards, S. W. The multifactorial role of neutrophils in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 593\u2013601 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1815_CR29","doi-asserted-by":"publisher","unstructured":"Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd3876 (2020).","DOI":"10.1126\/scitranslmed.abd3876"},{"key":"1815_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MOH.0b013e32834babdd","volume":"18","author":"S Muschter","year":"2011","unstructured":"Muschter, S., Berthold, T. & Greinacher, A. Developments in the definition and clinical impact of human neutrophil antigens. Curr. Opin. Hematol. 18, 452\u2013460 (2011).","journal-title":"Curr. Opin. Hematol."},{"key":"1815_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1006\/bcmd.2002.0513","volume":"28","author":"MT Elghetany","year":"2002","unstructured":"Elghetany, M. T. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol. Dis. 28, 260\u2013274 (2002).","journal-title":"Blood Cells Mol. Dis."},{"key":"1815_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1056\/NEJM197601152940318","volume":"294","author":"DR Boggs","year":"1976","unstructured":"Boggs, D. R. Granulocyte turnover in autoimmune neutropenia. N. Engl. J. Med. 294, 165 (1976).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR33","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1182\/bloodadvances.2020002793","volume":"4","author":"F Fioredda","year":"2020","unstructured":"Fioredda, F. et al. Late-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry. Blood Adv. 4, 5644\u20135649 (2020).","journal-title":"Blood Adv."},{"key":"1815_CR34","doi-asserted-by":"publisher","unstructured":"Audia, S., Grienay, N., Mounier, M., Michel, M. & Bonnotte, B. Evans\u2019 syndrome: from diagnosis to treatment. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm9123851 (2020).","DOI":"10.3390\/jcm9123851"},{"key":"1815_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12016-019-08774-5","volume":"58","author":"F Defendi","year":"2020","unstructured":"Defendi, F., Thielens, N. M., Clavarino, G., Cesbron, J. Y. & Dumestre-Perard, C. The immunopathology of complement proteins and innate immunity in autoimmune disease. Clin. Rev. Allergy Immunol. 58, 229\u2013251 (2020).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1815_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.molimm.2019.08.002","volume":"114","author":"J Schroder-Braunstein","year":"2019","unstructured":"Schroder-Braunstein, J. & Kirschfink, M. Complement deficiencies and dysregulation: pathophysiological consequences, modern analysis, and clinical management. Mol. Immunol. 114, 299\u2013311 (2019).","journal-title":"Mol. Immunol."},{"key":"1815_CR37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1128\/CMR.00048-09","volume":"23","author":"S Ram","year":"2010","unstructured":"Ram, S., Lewis, L. A. & Rice, P. A. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin. Microbiol. Rev. 23, 740\u2013780 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"1815_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0022-3476(76)80924-9","volume":"89","author":"D Lim","year":"1976","unstructured":"Lim, D. et al. Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J. Pediatr. 89, 42\u201347 (1976).","journal-title":"J. Pediatr."},{"key":"1815_CR39","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.4049\/jimmunol.154.10.5464","volume":"154","author":"X Wang","year":"1995","unstructured":"Wang, X. et al. Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families. J. Immunol. 154, 5464\u20135471 (1995).","journal-title":"J. Immunol."},{"key":"1815_CR40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1172\/JCI117868","volume":"95","author":"R Wurzner","year":"1995","unstructured":"Wurzner, R. et al. Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6. J. Clin. Invest. 95, 1877\u20131883 (1995).","journal-title":"J. Clin. Invest."},{"key":"1815_CR41","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.4049\/jimmunol.157.9.4239","volume":"157","author":"H Nishizaka","year":"1996","unstructured":"Nishizaka, H., Horiuchi, T., Zhu, Z. B., Fukumori, Y. & Volanakis, J. E. Genetic bases of human complement C7 deficiency. J. Immunol. 157, 4239\u20134243 (1996).","journal-title":"J. Immunol."},{"key":"1815_CR42","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.4049\/jimmunol.150.11.4943","volume":"150","author":"T Kaufmann","year":"1993","unstructured":"Kaufmann, T. et al. Genetic basis of human complement C8 beta deficiency. J. Immunol. 150, 4943\u20134947 (1993).","journal-title":"J. Immunol."},{"key":"1815_CR43","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJM196706152762409","volume":"276","author":"KF Austen","year":"1967","unstructured":"Austen, K. F. Inborn errors of the complement system of man. N. Engl. J. Med. 276, 1363\u20131368 (1967).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR44","first-page":"271","volume":"72","author":"J Rosain","year":"2014","unstructured":"Rosain, J. et al. Complement deficiencies and human diseases. Ann. Biol. Clin. 72, 271\u2013280 (2014).","journal-title":"Ann. Biol. Clin."},{"key":"1815_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1749-6632.2009.04633.x","volume":"1173","author":"HD Pettigrew","year":"2009","unstructured":"Pettigrew, H. D., Teuber, S. S. & Gershwin, M. E. Clinical significance of complement deficiencies. Ann. N. Y. Acad. Sci. 1173, 108\u2013123 (2009).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1815_CR46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri, F., Zuber, J., Fremeaux-Bacchi, V. & Loirat, C. Haemolytic uraemic syndrome. Lancet 390, 681\u2013696 (2017).","journal-title":"Lancet"},{"key":"1815_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part II: role in immunity. Front. Immunol. 6, 257 (2015).","journal-title":"Front. Immunol."},{"key":"1815_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.molimm.2022.08.011","volume":"151","author":"AT Matola","year":"2022","unstructured":"Matola, A. T., Jozsi, M. & Uzonyi, B. Overview on the role of complement-specific autoantibodies in diseases. Mol. Immunol. 151, 52\u201360 (2022).","journal-title":"Mol. Immunol."},{"key":"1815_CR49","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/ard.52.12.851","volume":"52","author":"CE Siegert","year":"1993","unstructured":"Siegert, C. E. et al. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann. Rheum. Dis. 52, 851\u2013856 (1993).","journal-title":"Ann. Rheum. Dis."},{"key":"1815_CR50","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1093\/ndt\/gfl436","volume":"21","author":"M Trendelenburg","year":"2006","unstructured":"Trendelenburg, M. et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol. Dial. Transpl. 21, 3115\u20133121 (2006).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1815_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/ard.2004.024943","volume":"64","author":"N Marto","year":"2005","unstructured":"Marto, N., Bertolaccini, M. L., Calabuig, E., Hughes, G. R. & Khamashta, M. A. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 444\u2013448 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"1815_CR52","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJM198305123081907","volume":"308","author":"KM Edwards","year":"1983","unstructured":"Edwards, K. M., Alford, R., Gewurz, H. & Mold, C. Recurrent bacterial infections associated with C3 nephritic factor and hypocomplementemia. N. Engl. J. Med. 308, 1138\u20131141 (1983).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR53","first-page":"153","volume":"52","author":"RA Thompson","year":"1983","unstructured":"Thompson, R. A., Yap, P. L., Brettle, R. B., Dunmow, R. E. & Chapel, H. Meningococcal meningitis associated with persistent hypocomplementaemia due to circulating C3 nephritic factor. Clin. Exp. Immunol. 52, 153\u2013156 (1983).","journal-title":"Clin. Exp. Immunol."},{"key":"1815_CR54","first-page":"341","volume":"92","author":"B Teisner","year":"1984","unstructured":"Teisner, B. et al. C3 nephritic factor in a patient with recurrent Neisseria meningitidis infections. Acta Pathol. Microbiol. Immunol. Scand. C. 92, 341\u2013349 (1984).","journal-title":"Acta Pathol. Microbiol. Immunol. Scand. C."},{"key":"1815_CR55","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1073\/pnas.74.9.3980","volume":"74","author":"AE Davis 3rd","year":"1977","unstructured":"Davis, A. E. 3rd, Ziegler, J. B., Gelfand, E. W., Rosen, F. S. & Alper, C. A. Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc. Natl Acad. Sci. USA 74, 3980\u20133983 (1977).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1815_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","volume":"116","author":"MR Daha","year":"1976","unstructured":"Daha, M. R., Fearon, D. T. & Austen, K. F. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J. Immunol. 116, 1\u20137 (1976).","journal-title":"J. Immunol."},{"key":"1815_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101331","volume":"45","author":"K Kaartinen","year":"2019","unstructured":"Kaartinen, K., Safa, A., Kotha, S., Ratti, G. & Meri, S. Complement dysregulation in glomerulonephritis. Semin. Immunol. 45, 101331 (2019).","journal-title":"Semin. Immunol."},{"key":"1815_CR58","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00467-018-3989-0","volume":"34","author":"M Noris","year":"2019","unstructured":"Noris, M., Donadelli, R. & Remuzzi, G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr. Nephrol. 34, 1311\u20131323 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"1815_CR59","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear, H. M., Schoggins, J. W. & Diamond, M. S. Shared and distinct functions of type I and type III Interferons. Immunity 50, 907\u2013923 (2019).","journal-title":"Immunity"},{"key":"1815_CR60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(81)91460-4","volume":"2","author":"KE Mogensen","year":"1981","unstructured":"Mogensen, K. E., Daubas, P., Gresser, I., Sereni, D. & Varet, B. Patient with circulating antibodies to alpha-interferon. Lancet 2, 1227\u20131228 (1981).","journal-title":"Lancet"},{"key":"1815_CR61","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/infdis\/150.5.707","volume":"150","author":"B Pozzetto","year":"1984","unstructured":"Pozzetto, B., Mogensen, K. E., Tovey, M. G. & Gresser, I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J. Infect. Dis. 150, 707\u2013713 (1984).","journal-title":"J. Infect. Dis."},{"key":"1815_CR62","doi-asserted-by":"publisher","unstructured":"Casanova, J. L. & Anderson, M. S. Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI166283 (2023).","DOI":"10.1172\/JCI166283"},{"key":"1815_CR63","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abl4340 (2021).","DOI":"10.1126\/sciimmunol.abl4340"},{"key":"1815_CR64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200413119","volume":"119","author":"J Manry","year":"2022","unstructured":"Manry, J. et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc. Natl Acad. Sci. USA 119, e2200413119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1815_CR65","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abp8966 (2022).","DOI":"10.1126\/sciimmunol.abp8966"},{"key":"1815_CR66","doi-asserted-by":"publisher","unstructured":"Sokal, A. et al. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20220258 (2023).","DOI":"10.1084\/jem.20220258"},{"key":"1815_CR67","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20202486 (2021).","DOI":"10.1084\/jem.20202486"},{"key":"1815_CR68","doi-asserted-by":"publisher","unstructured":"Zhang, Q. et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20220514 (2022).","DOI":"10.1084\/jem.20220514"},{"key":"1815_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13116","volume":"17","author":"F Alotaibi","year":"2023","unstructured":"Alotaibi, F. et al. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial. Influenza Other Respir. Viruses 17, e13116 (2023).","journal-title":"Influenza Other Respir. Viruses"},{"key":"1815_CR70","doi-asserted-by":"publisher","unstructured":"Gervais, A. et al. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20230661 (2023).","DOI":"10.1084\/jem.20230661"},{"key":"1815_CR71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1365-2796.2007.01786.x","volume":"261","author":"S Nagafuchi","year":"2007","unstructured":"Nagafuchi, S. et al. Recurrent herpes simplex virus infection in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy associated with L29P and IVS9-1G>C compound heterozygous autoimmune regulator gene mutations. J. Intern. Med. 261, 605\u2013610 (2007).","journal-title":"J. Intern. Med."},{"key":"1815_CR72","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1136\/ard-2022-222549","volume":"81","author":"A Mathian","year":"2022","unstructured":"Mathian, A. et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-\u03b1. Ann. Rheum. Dis. 81, 1695\u20131703 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1815_CR73","doi-asserted-by":"publisher","first-page":"108851","DOI":"10.1016\/j.clim.2021.108851","volume":"231","author":"I Hetem\u00e4ki","year":"2021","unstructured":"Hetem\u00e4ki, I. et al. Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections. Clin. Immunol. 231, 108851 (2021).","journal-title":"Clin. Immunol."},{"key":"1815_CR74","doi-asserted-by":"publisher","first-page":"e3001709","DOI":"10.1371\/journal.pbio.3001709","volume":"20","author":"I Busnadiego","year":"2022","unstructured":"Busnadiego, I. et al. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biol. 20, e3001709 (2022).","journal-title":"PLoS Biol."},{"key":"1815_CR75","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/01.mpg.0000243432.09216.aa","volume":"44","author":"A Batra","year":"2007","unstructured":"Batra, A. et al. Varicella recurrence complicated by pneumonia after liver transplantation for APECED. J. Pediatr. Gastroenterol. Nutr. 44, 637\u2013639 (2007).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1815_CR76","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1172\/JCI80477","volume":"125","author":"JE Walter","year":"2015","unstructured":"Walter, J. E. et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J. Clin. Invest. 125, 4135\u20134148 (2015).","journal-title":"J. Clin. Invest."},{"key":"1815_CR77","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.coi.2022.01.003","volume":"74","author":"P Bastard","year":"2022","unstructured":"Bastard, P., Zhang, Q., Zhang, S. Y., Jouanguy, E. & Casanova, J. L. Type I interferons and SARS-CoV-2: from cells to organisms. Curr. Opin. Immunol. 74, 172\u2013182 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"1815_CR78","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10875-021-01203-3","volume":"42","author":"A Chauvineau-Grenier","year":"2022","unstructured":"Chauvineau-Grenier, A. et al. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J. Clin. Immunol. 42, 459\u2013470 (2022).","journal-title":"J. Clin. Immunol."},{"key":"1815_CR79","doi-asserted-by":"publisher","first-page":"e20231353","DOI":"10.1084\/jem.20231353","volume":"221","author":"P Bastard","year":"2024","unstructured":"Bastard, P. et al. Higher COVID-19 pneumonia risk associated with anti-IFN-\u03b1 than with anti-IFN-\u03c9 auto-Abs in children. J. Exp. Med. 221, e20231353 (2024).","journal-title":"J. Exp. Med."},{"key":"1815_CR80","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/289496a0","volume":"289","author":"A Vallbracht","year":"1981","unstructured":"Vallbracht, A., Treuner, J., Flehmig, B., Joester, K. E. & Niethammer, D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289, 496\u2013497 (1981).","journal-title":"Nature"},{"key":"1815_CR81","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/1097-0142(19870201)59:3+<668::AID-CNCR2820591317>3.0.CO;2-J","volume":"59","author":"LM Itri","year":"1987","unstructured":"Itri, L. M. et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 59, 668\u2013674 (1987).","journal-title":"Cancer"},{"key":"1815_CR82","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/jir.1994.14.205","volume":"14","author":"G Fierlbeck","year":"1994","unstructured":"Fierlbeck, G. & Schreiner, T. Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-beta. J. Interferon Res. 14, 205\u2013206 (1994).","journal-title":"J. Interferon Res."},{"key":"1815_CR83","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/intimm\/dxg088","volume":"15","author":"H Shiono","year":"2003","unstructured":"Shiono, H. et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 15, 903\u2013913 (2003).","journal-title":"Int. Immunol."},{"key":"1815_CR84","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/S0140-6736(05)64012-3","volume":"350","author":"A Meager","year":"1997","unstructured":"Meager, A., Vincent, A., Newsom-Davis, J. & Willcox, N. Spontaneous neutralising antibodies to interferon\u2013alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet 350, 1596\u20131597 (1997).","journal-title":"Lancet"},{"key":"1815_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.129.1.1","volume":"129","author":"S Panem","year":"1982","unstructured":"Panem, S., Check, I. J., Henriksen, D. & Vilcek, J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J. Immunol. 129, 1\u20133 (1982).","journal-title":"J. Immunol."},{"key":"1815_CR86","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","volume":"3","author":"A Meager","year":"2006","unstructured":"Meager, A. et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e289 (2006).","journal-title":"PLoS Med."},{"key":"1815_CR87","doi-asserted-by":"publisher","first-page":"e20210554","DOI":"10.1084\/jem.20210554","volume":"218","author":"P Bastard","year":"2021","unstructured":"Bastard, P. et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218, e20210554 (2021).","journal-title":"J. Exp. Med."},{"key":"1815_CR88","doi-asserted-by":"crossref","unstructured":"Husebye, E. S., Anderson, M. S. & K\u00e4mpe, O. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 378, 1132\u20131141 (2018).","DOI":"10.1056\/NEJMra1713301"},{"key":"1815_CR89","doi-asserted-by":"publisher","unstructured":"Oftedal, B. E., Sj\u00f8gren, T. & Wolff, A. S. B. Interferon autoantibodies as signals of a sick thymus. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1327784 (2024).","DOI":"10.3389\/fimmu.2024.1327784"},{"key":"1815_CR90","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41586-023-06717-x","volume":"623","author":"T Le Voyer","year":"2023","unstructured":"Le Voyer, T. et al. Autoantibodies against type I IFNs in humans with alternative NF-\u03baB pathway deficiency. Nature 623, 803\u2013813 (2023).","journal-title":"Nature"},{"key":"1815_CR91","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.4049\/jimmunol.1401068","volume":"193","author":"AS Wolff","year":"2014","unstructured":"Wolff, A. S. et al. Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. J. Immunol. 193, 3880\u20133890 (2014).","journal-title":"J. Immunol."},{"key":"1815_CR92","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/path.2141","volume":"211","author":"P Strobel","year":"2007","unstructured":"Strobel, P. et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J. Pathol. 211, 563\u2013571 (2007).","journal-title":"J. Pathol."},{"key":"1815_CR93","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc0909510","volume":"362","author":"MH Cheng","year":"2010","unstructured":"Cheng, M. H. et al. Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect. N. Engl. J. Med. 362, 764\u2013766 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR94","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3389\/fimmu.2018.00544","volume":"9","author":"JM Rosenberg","year":"2018","unstructured":"Rosenberg, J. M. et al. Neutralizing anti-cytokine autoantibodies against interferon-alpha in immunodysregulation polyendocrinopathy enteropathy X-linked. Front. Immunol. 9, 544 (2018).","journal-title":"Front. Immunol."},{"key":"1815_CR95","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaci.2013.11.038","volume":"133","author":"K Chen","year":"2014","unstructured":"Chen, K. et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1\/2 mutations. J. Allergy Clin. Immunol. 133, 880\u2013882 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1815_CR96","unstructured":"Rosain, J. Thymic dysplasia underlies anti-type I IFN autoantibody production and viral diseases in women with incontinentia pigmenti. J. Exp. Med. Under review (2023)."},{"key":"1815_CR97","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe3454","volume":"6","author":"I Hetemaki","year":"2021","unstructured":"Hetemaki, I. et al. Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells. Sci. Immunol. 6, eabe3454 (2021).","journal-title":"Sci. Immunol."},{"key":"1815_CR98","unstructured":"Materna, M. et al. The immunopathological landscape of human pre-TCRa deficiency: from rare to common variants. Science 383, eadh4059 (2024)."},{"key":"1815_CR99","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1084\/jem.158.3.670","volume":"158","author":"CF Nathan","year":"1983","unstructured":"Nathan, C. F., Murray, H. W., Wiebe, M. E. & Rubin, B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158, 670\u2013689 (1983).","journal-title":"J. Exp. Med."},{"key":"1815_CR100","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1189\/jlb.0603252","volume":"75","author":"K Schroder","year":"2004","unstructured":"Schroder, K., Hertzog, P. J., Ravasi, T. & Hume, D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163\u2013189 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"1815_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102296","volume":"81","author":"M Ogishi","year":"2023","unstructured":"Ogishi, M. et al. Inborn errors of human transcription factors governing IFN-gamma antimycobacterial immunity. Curr. Opin. Immunol. 81, 102296 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"1815_CR102","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.coi.2021.07.001","volume":"72","author":"S Boisson-Dupuis","year":"2021","unstructured":"Boisson-Dupuis, S. & Bustamante, J. Mycobacterial diseases in patients with inborn errors of immunity. Curr. Opin. Immunol. 72, 262\u2013271 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"1815_CR103","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.smim.2014.09.008","volume":"26","author":"J Bustamante","year":"2014","unstructured":"Bustamante, J., Boisson-Dupuis, S., Abel, L. & Casanova, J. L. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin. Immunol. 26, 454\u2013470 (2014).","journal-title":"Semin. Immunol."},{"key":"1815_CR104","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1172\/JCI135460","volume":"130","author":"G Kerner","year":"2020","unstructured":"Kerner, G. et al. Inherited human IFN-gamma deficiency underlies mycobacterial disease. J. Clin. Invest. 130, 3158\u20133171 (2020).","journal-title":"J. Clin. Invest."},{"key":"1815_CR105","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00439-020-02180-0","volume":"139","author":"CL Ku","year":"2020","unstructured":"Ku, C. L., Chi, C. Y., von Bernuth, H. & Doffinger, R. Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Hum. Genet 139, 783\u2013794 (2020).","journal-title":"Hum. Genet"},{"key":"1815_CR106","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.coi.2021.05.007","volume":"72","author":"HP Shih","year":"2021","unstructured":"Shih, H. P., Ding, J. Y., Yeh, C. F., Chi, C. Y. & Ku, C. L. Anti-interferon-gamma autoantibody-associated immunodeficiency. Curr. Opin. Immunol. 72, 206\u2013214 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"1815_CR107","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1086\/380453","volume":"38","author":"R Doffinger","year":"2004","unstructured":"Doffinger, R. et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38, e10\u2013e14 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"1815_CR108","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood-2003-04-1065","volume":"103","author":"C Hoflich","year":"2004","unstructured":"Hoflich, C. et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103, 673\u2013675 (2004).","journal-title":"Blood"},{"key":"1815_CR109","doi-asserted-by":"publisher","unstructured":"Puel, A., Bastard, P., Bustamante, J. & Casanova, J. L. Human autoantibodies underlying infectious diseases. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20211387 (2022).","DOI":"10.1084\/jem.20211387"},{"key":"1815_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051673","volume":"13","author":"Y Qiu","year":"2022","unstructured":"Qiu, Y. et al. Pathogen spectrum and immunotherapy in patients with anti-IFN-gamma autoantibodies: a multicenter retrospective study and systematic review. Front. Immunol. 13, 1051673 (2022).","journal-title":"Front. Immunol."},{"key":"1815_CR111","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1111160","volume":"367","author":"SK Browne","year":"2012","unstructured":"Browne, S. K. et al. Adult-onset immunodeficiency in Thailand and Taiwan. N. Engl. J. Med. 367, 725\u2013734 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR112","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s15010-010-0067-3","volume":"39","author":"T Kampitak","year":"2011","unstructured":"Kampitak, T., Suwanpimolkul, G., Browne, S. & Suankratay, C. Anti-interferon-gamma autoantibody and opportunistic infections: case series and review of the literature. Infection 39, 65\u201371 (2011).","journal-title":"Infection"},{"key":"1815_CR113","doi-asserted-by":"publisher","first-page":"e76371","DOI":"10.1371\/journal.pone.0076371","volume":"8","author":"P Wongkulab","year":"2013","unstructured":"Wongkulab, P., Wipasa, J., Chaiwarith, R. & Supparatpinyo, K. Autoantibody to interferon-gamma associated with adult-onset immunodeficiency in non-HIV individuals in northern Thailand. PLoS ONE 8, e76371 (2013).","journal-title":"PLoS ONE"},{"key":"1815_CR114","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1128\/CVI.00053-10","volume":"17","author":"BS Tang","year":"2010","unstructured":"Tang, B. S. et al. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon. Clin. Vaccin. Immunol. 17, 1132\u20131138 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1815_CR115","doi-asserted-by":"publisher","unstructured":"Guo, J. et al. Anti-IFN-gamma autoantibodies underlie disseminated Talaromyces marneffei infections. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20190502 (2020).","DOI":"10.1084\/jem.20190502"},{"key":"1815_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz208","volume":"6","author":"W Zeng","year":"2019","unstructured":"Zeng, W. et al. Characterization of anti-interferon-gamma antibodies in HIV-negative patients infected with disseminated Talaromyces marneffei and Cryptococcosis. Open Forum Infect. Dis. 6, ofz208 (2019).","journal-title":"Open Forum Infect. Dis."},{"key":"1815_CR117","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1182\/blood-2012-08-452482","volume":"121","author":"CY Chi","year":"2013","unstructured":"Chi, C. Y. et al. Anti-IFN-gamma autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood 121, 1357\u20131366 (2013).","journal-title":"Blood"},{"key":"1815_CR118","doi-asserted-by":"publisher","first-page":"e0128481","DOI":"10.1371\/journal.pone.0128481","volume":"10","author":"M Pithukpakorn","year":"2015","unstructured":"Pithukpakorn, M. et al. HLA-DRB1 and HLA-DQB1 are associated with adult-onset immunodeficiency with acquired anti-interferon-gamma autoantibodies. PLoS ONE 10, e0128481 (2015).","journal-title":"PLoS ONE"},{"key":"1815_CR119","doi-asserted-by":"publisher","first-page":"e3927","DOI":"10.1097\/MD.0000000000003927","volume":"95","author":"CY Chi","year":"2016","unstructured":"Chi, C. Y. et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-gamma autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine 95, e3927 (2016).","journal-title":"Medicine"},{"key":"1815_CR120","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.4049\/jimmunol.175.7.4769","volume":"175","author":"SY Patel","year":"2005","unstructured":"Patel, S. Y. et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J. Immunol. 175, 4769\u20134776 (2005).","journal-title":"J. Immunol."},{"key":"1815_CR121","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cid\/ciz786","volume":"71","author":"GH Hong","year":"2020","unstructured":"Hong, G. H. et al. Natural history and evolution of Anti-Interferon-gamma autoantibody-associated immunodeficiency syndrome in Thailand and the United States. Clin. Infect. Dis. 71, 53\u201362 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1815_CR122","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaci.2015.09.018","volume":"137","author":"CL Ku","year":"2016","unstructured":"Ku, C. L. et al. Anti-IFN-gamma autoantibodies are strongly associated with HLA-DR*15:02\/16:02 and HLA-DQ*05:01\/05:02 across Southeast Asia. J. Allergy Clin. Immunol. 137, 945\u2013948 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1815_CR123","doi-asserted-by":"publisher","unstructured":"Shih, H. P. et al. Pathogenic autoantibodies to IFN-gamma act through the impedance of receptor assembly and Fc-mediated response. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20212126 (2022).","DOI":"10.1084\/jem.20212126"},{"key":"1815_CR124","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/nm.4158","volume":"22","author":"CH Lin","year":"2016","unstructured":"Lin, C. H. et al. Identification of a major epitope by anti-interferon-gamma autoantibodies in patients with mycobacterial disease. Nat. Med. 22, 994\u20131001 (2016).","journal-title":"Nat. Med."},{"key":"1815_CR125","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/imcb.12210","volume":"97","author":"J Rosain","year":"2019","unstructured":"Rosain, J. et al. Mendelian susceptibility to mycobacterial disease: 2014\u20132018 update. Immunol. Cell Biol. 97, 360\u2013367 (2019).","journal-title":"Immunol. Cell Biol."},{"key":"1815_CR126","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","volume":"11","author":"CN Ratnatunga","year":"2020","unstructured":"Ratnatunga, C. N. et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol. 11, 303 (2020).","journal-title":"Front Immunol."},{"key":"1815_CR127","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/jac\/32.suppl_A.99","volume":"32","author":"A Turano","year":"1993","unstructured":"Turano, A. & Caruso, A. The role of human autoantibodies against gamma-interferon. J. Antimicrob. Chemother. 32, 99\u2013105 (1993).","journal-title":"J. Antimicrob. Chemother."},{"key":"1815_CR128","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF02678215","volume":"10","author":"A Caruso","year":"1997","unstructured":"Caruso, A. & Turano, A. Natural antibodies to interferon-gamma. Biotherapy 10, 29\u201337 (1997).","journal-title":"Biotherapy"},{"key":"1815_CR129","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4049\/jimmunol.144.2.685","volume":"144","author":"A Caruso","year":"1990","unstructured":"Caruso, A. et al. Natural antibodies to IFN-gamma in man and their increase during viral infection. J. Immunol. 144, 685\u2013690 (1990).","journal-title":"J. Immunol."},{"key":"1815_CR130","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1073\/pnas.89.10.4447","volume":"89","author":"A Turano","year":"1992","unstructured":"Turano, A. et al. Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine. Proc. Natl Acad. Sci. USA 89, 4447\u20134451 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1815_CR131","doi-asserted-by":"publisher","first-page":"e88782","DOI":"10.1172\/jci.insight.88782","volume":"1","author":"EM Ferre","year":"2016","unstructured":"Ferre, E. M. et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 1, e88782 (2016).","journal-title":"JCI Insight"},{"key":"1815_CR132","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9, 556\u2013567 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1815_CR133","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nri2800","volume":"10","author":"DJ Cua","year":"2010","unstructured":"Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10, 479\u2013489 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1815_CR134","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/cr.2007.35","volume":"17","author":"SH Chang","year":"2007","unstructured":"Chang, S. H. & Dong, C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 17, 435\u2013440 (2007).","journal-title":"Cell Res."},{"key":"1815_CR135","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","volume":"23","author":"KHG Mills","year":"2023","unstructured":"Mills, K. H. G. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 23, 38\u201354 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1815_CR136","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","volume":"181","author":"JF Wright","year":"2008","unstructured":"Wright, J. F. et al. The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex. J. Immunol. 181, 2799\u20132805 (2008).","journal-title":"J. Immunol."},{"key":"1815_CR137","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1126\/science.1200439","volume":"332","author":"A Puel","year":"2011","unstructured":"Puel, A. et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65\u201368 (2011).","journal-title":"Science"},{"key":"1815_CR138","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.20141065","volume":"212","author":"Y Ling","year":"2015","unstructured":"Ling, Y. et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 212, 619\u2013631 (2015).","journal-title":"J. Exp. Med."},{"key":"1815_CR139","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaip.2023.04.015","volume":"11","author":"SG Tangye","year":"2023","unstructured":"Tangye, S. G. & Puel, A. The Th17\/IL-17 axis and host defense against fungal infections. J. Allergy Clin. Immunol. Pract. 11, 1624\u20131634 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1815_CR140","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.cellsig.2010.11.022","volume":"23","author":"SH Chang","year":"2011","unstructured":"Chang, S. H. & Dong, C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell. Signal. 23, 1069\u20131075 (2011).","journal-title":"Cell. Signal."},{"key":"1815_CR141","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni.1813","volume":"10","author":"LK Ely","year":"2009","unstructured":"Ely, L. K., Fischer, S. & Garcia, K. C. Structural basis of receptor sharing by interleukin 17 cytokines. Nat. Immunol. 10, 1245\u20131251 (2009).","journal-title":"Nat. Immunol."},{"key":"1815_CR142","doi-asserted-by":"publisher","first-page":"eaau9657","DOI":"10.1126\/sciimmunol.aau9657","volume":"4","author":"Y Su","year":"2019","unstructured":"Su, Y. et al. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci. Immunol. 4, eaau9657 (2019).","journal-title":"Sci. Immunol."},{"key":"1815_CR143","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","volume":"207","author":"K Kisand","year":"2010","unstructured":"Kisand, K. et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207, 299\u2013308 (2010).","journal-title":"J. Exp. Med."},{"key":"1815_CR144","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1084\/jem.20091983","volume":"207","author":"A Puel","year":"2010","unstructured":"Puel, A. et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207, 291\u2013297 (2010).","journal-title":"J. Exp. Med."},{"key":"1815_CR145","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi5459","volume":"373","author":"A Puel","year":"2021","unstructured":"Puel, A. & Casanova, J. L. Comment on \u2018aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science 373, eabi5459 (2021).","journal-title":"Science"},{"key":"1815_CR146","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.coi.2010.06.009","volume":"22","author":"A Puel","year":"2010","unstructured":"Puel, A. et al. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr. Opin. Immunol. 22, 467\u2013474 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"1815_CR147","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/eji.201041253","volume":"41","author":"K Kisand","year":"2011","unstructured":"Kisand, K. et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur. J. Immunol. 41, 1517\u20131527 (2011).","journal-title":"Eur. J. Immunol."},{"key":"1815_CR148","doi-asserted-by":"publisher","first-page":"eabi6235","DOI":"10.1126\/science.abi6235","volume":"373","author":"K Kisand","year":"2021","unstructured":"Kisand, K., Meager, A., Hayday, A. & Willcox, N. Comment on \u201cAberrant type 1 immunity drives susceptibility to mucosal fungal infections\u201d. Science 373, eabi6235 (2021).","journal-title":"Science"},{"key":"1815_CR149","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cei\/uxac040","volume":"208","author":"N Sharifinejad","year":"2022","unstructured":"Sharifinejad, N. et al. The clinical, molecular, and therapeutic features of patients with IL10\/IL10R deficiency: a systematic review. Clin. Exp. Immunol. 208, 281\u2013291 (2022).","journal-title":"Clin. Exp. Immunol."},{"key":"1815_CR150","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.4049\/jimmunol.1401467","volume":"193","author":"Y Yamazaki","year":"2014","unstructured":"Yamazaki, Y. et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody. J. Immunol. 193, 4880\u20134887 (2014).","journal-title":"J. Immunol."},{"key":"1815_CR151","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1815_CR152","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano, T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 33, 127\u2013148 (2021).","journal-title":"Int. Immunol."},{"key":"1815_CR153","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy, E. H. et al. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335\u2013345 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1815_CR154","doi-asserted-by":"crossref","unstructured":"Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M. & Scheller, J. Targeting IL-6 trans-signalling: past present and future prospects. Nat. Rev. Immunol. 23, 666\u2013681 (2023).","DOI":"10.1038\/s41577-023-00856-y"},{"key":"1815_CR155","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1084\/jem.20190344","volume":"216","author":"S Spencer","year":"2019","unstructured":"Spencer, S. et al. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J. Exp. Med. 216, 1986\u20131998 (2019).","journal-title":"J. Exp. Med."},{"key":"1815_CR156","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jaci.2019.11.015","volume":"145","author":"A Nahum","year":"2020","unstructured":"Nahum, A. et al. Defining the biological responses of IL-6 by the study of a novel IL-6 receptor chain immunodeficiency. J. Allergy Clin. Immunol. 145, 1011\u20131015 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1815_CR157","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.coi.2021.04.007","volume":"72","author":"YH Chen","year":"2021","unstructured":"Chen, Y. H., Spencer, S., Laurence, A., Thaventhiran, J. E. & Uhlig, H. H. Inborn errors of IL-6 family cytokine responses. Curr. Opin. Immunol. 72, 135\u2013145 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"1815_CR158","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1084\/jem.20191002","volume":"216","author":"A Puel","year":"2019","unstructured":"Puel, A. & Casanova, J. L. The nature of human IL-6. J. Exp. Med. 216, 1969\u20131971 (2019).","journal-title":"J. Exp. Med."},{"key":"1815_CR159","doi-asserted-by":"publisher","unstructured":"Beziat, V. et al. Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191804 (2020).","DOI":"10.1084\/jem.20191804"},{"key":"1815_CR160","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jaci.2021.02.044","volume":"148","author":"YH Chen","year":"2021","unstructured":"Chen, Y. H. et al. Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome. J. Allergy Clin. Immunol. 148, 585\u2013598 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1815_CR161","first-page":"1566","volume":"43","author":"T Arlabosse","year":"2023","unstructured":"Arlabosse, T. et al. New dominant-negative IL6ST variants expand the immunological and clinical spectrum of GP130-Dependent Hyper-IgE syndrome. J. Clin. Immunol. 43, 1566\u20131580 (2023).","journal-title":"J. Clin. Immunol."},{"key":"1815_CR162","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4049\/jimmunol.180.1.647","volume":"180","author":"A Puel","year":"2008","unstructured":"Puel, A. et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180, 647\u2013654 (2008).","journal-title":"J. Immunol."},{"key":"1815_CR163","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3389\/fimmu.2019.02629","volume":"10","author":"M Bloomfield","year":"2019","unstructured":"Bloomfield, M. et al. Anti-IL6 autoantibodies in an infant with CRP-less septic shock. Front. Immunol. 10, 2629 (2019).","journal-title":"Front. Immunol."},{"key":"1815_CR164","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/annrheumdis-2012-202768","volume":"72","author":"T Nanki","year":"2013","unstructured":"Nanki, T. et al. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann. Rheum. Dis. 72, 1100\u20131102 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1815_CR165","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/eji.200425268","volume":"34","author":"P Galle","year":"2004","unstructured":"Galle, P., Svenson, M., Bendtzen, K. & Hansen, M. B. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur. J. Immunol. 34, 3267\u20133275 (2004).","journal-title":"Eur. J. Immunol."},{"key":"1815_CR166","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/iid3.109","volume":"4","author":"J Karner","year":"2016","unstructured":"Karner, J. et al. IL-6-specific autoantibodies among APECED and thymoma patients. Immun. Inflamm. Dis. 4, 235\u2013243 (2016).","journal-title":"Immun. Inflamm. Dis."},{"key":"1815_CR167","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1365-3083.1991.tb02552.x","volume":"33","author":"MB Hansen","year":"1991","unstructured":"Hansen, M. B., Svenson, M., Diamant, M. & Bendtzen, K. Anti-interleukin-6 antibodies in normal human serum. Scand. J. Immunol. 33, 777\u2013781 (1991).","journal-title":"Scand. J. Immunol."},{"key":"1815_CR168","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/1043-4666(93)90026-2","volume":"5","author":"MB Hansen","year":"1993","unstructured":"Hansen, M. B., Svenson, M., Diamant, M. & Bendtzen, K. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 5, 72\u201380 (1993).","journal-title":"Cytokine"},{"key":"1815_CR169","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1172\/JCI116862","volume":"92","author":"M Svenson","year":"1993","unstructured":"Svenson, M., Hansen, M. B. & Bendtzen, K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 92, 2533\u20132539 (1993).","journal-title":"J. Clin. Invest."},{"key":"1815_CR170","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cyto.2015.05.030","volume":"75","author":"P Bhattacharya","year":"2015","unstructured":"Bhattacharya, P. et al. GM-CSF: an immune modulatory cytokine that can suppress autoimmunity. Cytokine 75, 261\u2013271 (2015).","journal-title":"Cytokine"},{"key":"1815_CR171","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1002\/j.1460-2075.1989.tb08541.x","volume":"8","author":"DP Gearing","year":"1989","unstructured":"Gearing, D. P., King, J. A., Gough, N. M. & Nicola, N. A. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J. 8, 3667\u20133676 (1989).","journal-title":"EMBO J."},{"key":"1815_CR172","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1073\/pnas.87.24.9655","volume":"87","author":"K Hayashida","year":"1990","unstructured":"Hayashida, K. et al. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc. Natl Acad. Sci. USA 87, 9655\u20139659 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1815_CR173","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1172\/JCI119758","volume":"100","author":"U Dirksen","year":"1997","unstructured":"Dirksen, U. et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF\/IL-3\/IL-5 receptor common beta chain expression. J. Clin. Invest. 100, 2211\u20132217 (1997).","journal-title":"J. Clin. Invest."},{"key":"1815_CR174","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM195806052582301","volume":"258","author":"SH Rosen","year":"1958","unstructured":"Rosen, S. H., Castleman, B. & Liebow, A. A. Pulmonary alveolar proteinosis. N. Engl. J. Med. 258, 1123\u20131142 (1958).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR175","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-019-0066-3","volume":"5","author":"BC Trapnell","year":"2019","unstructured":"Trapnell, B. C. et al. Pulmonary alveolar proteinosis. Nat. Rev. Dis. Primers 5, 16 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1815_CR176","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1084\/jem.190.6.875","volume":"190","author":"T Kitamura","year":"1999","unstructured":"Kitamura, T. et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte\/macrophage colony-stimulating factor. J. Exp. Med. 190, 875\u2013880 (1999).","journal-title":"J. Exp. Med."},{"key":"1815_CR177","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.4049\/jimmunol.1202526","volume":"190","author":"LB Rosen","year":"2013","unstructured":"Rosen, L. B. et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J. Immunol. 190, 3959\u20133966 (2013).","journal-title":"J. Immunol."},{"key":"1815_CR178","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10875-020-00796-5","volume":"40","author":"S Perrineau","year":"2020","unstructured":"Perrineau, S., Guery, R., Monnier, D., Puel, A. & Lanternier, F. Anti-GM-CSF autoantibodies and Cryptococcus neoformans var. grubii CNS vasculitis. J. Clin. Immunol. 40, 767\u2013769 (2020).","journal-title":"J. Clin. Immunol."},{"key":"1815_CR179","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10875-016-0364-4","volume":"37","author":"CY Kuo","year":"2017","unstructured":"Kuo, C. Y. et al. Disseminated cryptococcosis due to anti-granulocyte-macrophage colony-stimulating factor autoantibodies in the absence of pulmonary alveolar proteinosis. J. Clin. Immunol. 37, 143\u2013152 (2017).","journal-title":"J. Clin. Immunol."},{"key":"1815_CR180","doi-asserted-by":"publisher","first-page":"e00912","DOI":"10.1128\/mBio.00912-14","volume":"5","author":"T Saijo","year":"2014","unstructured":"Saijo, T. et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio 5, e00912\u2013e00914 (2014).","journal-title":"mBio"},{"key":"1815_CR181","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/jpids\/piy100","volume":"9","author":"J Huynh","year":"2020","unstructured":"Huynh, J. et al. Unusual presentation of severe endobronchial obstruction caused by Cryptococcus gattii in a child. J. Pediatr. Infect. Dis. Soc. 9, 67\u201370 (2020).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"1815_CR182","doi-asserted-by":"publisher","unstructured":"Applen Clancey, S. et al. Cryptococcus deuterogattii VGIIa infection associated with travel to the pacific northwest outbreak region in an anti-granulocyte-macrophage colony-stimulating factor autoantibody-positive patient in the United States. mBio https:\/\/doi.org\/10.1128\/mBio.02733-18 (2019).","DOI":"10.1128\/mBio.02733-18"},{"key":"1815_CR183","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/imj.14637","volume":"49","author":"B Stevenson","year":"2019","unstructured":"Stevenson, B. et al. The significance of anti-granulocyte-macrophage colony-stimulating factor antibodies in cryptococcal infection: case series and review of antibody testing. Intern. Med. J. 49, 1446\u20131450 (2019).","journal-title":"Intern. Med. J."},{"key":"1815_CR184","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/myc.13247","volume":"64","author":"GM Viola","year":"2021","unstructured":"Viola, G. M. et al. Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: an underappreciated association. Mycoses 64, 576\u2013582 (2021).","journal-title":"Mycoses"},{"key":"1815_CR185","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx082","volume":"4","author":"AA Panackal","year":"2017","unstructured":"Panackal, A. A. et al. Susceptibility to Cryptococcal Meningoencephalitis associated with idiopathic CD4+ lymphopenia and secondary germline or acquired defects. Open Forum Infect. Dis. 4, ofx082 (2017).","journal-title":"Open Forum Infect. Dis."},{"key":"1815_CR186","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx211","volume":"4","author":"NF Crum-Cianflone","year":"2017","unstructured":"Crum-Cianflone, N. F., Lam, P. V., Ross-Walker, S., Rosen, L. B. & Holland, S. M. Autoantibodies to granulocyte-macrophage colony-stimulating factor associated with severe and unusual manifestations of Cryptococcus gattii infections. Open Forum Infect. Dis. 4, ofx211 (2017).","journal-title":"Open Forum Infect. Dis."},{"key":"1815_CR187","doi-asserted-by":"publisher","unstructured":"Demir, S., Chebib, N., Thivolet-Bejui, F. & Cottin, V. Pulmonary alveolar proteinosis following cryptococcal meningitis: a possible cause? BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2017-222940 (2018).","DOI":"10.1136\/bcr-2017-222940"},{"key":"1815_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220040","author":"A Mabo","year":"2023","unstructured":"Mabo, A. et al. Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort. Thorax https:\/\/doi.org\/10.1136\/thorax-2023-220040 (2023).","journal-title":"Thorax"},{"key":"1815_CR189","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.2169\/internalmedicine.54.5034","volume":"54","author":"T Arai","year":"2015","unstructured":"Arai, T., Inoue, Y., Akira, M., Nakata, K. & Kitaichi, M. Autoimmune pulmonary alveolar proteinosis following pulmonary aspergillosis. Intern. Med. 54, 3177\u20133180 (2015).","journal-title":"Intern. Med."},{"key":"1815_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752856","volume":"12","author":"A Ataya","year":"2021","unstructured":"Ataya, A. et al. The Role of GM-CSF autoantibodies in infection and autoimmune pulmonary alveolar proteinosis: a concise review. Front. Immunol. 12, 752856 (2021).","journal-title":"Front. Immunol."},{"key":"1815_CR191","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa062505","volume":"356","author":"K Uchida","year":"2007","unstructured":"Uchida, K. et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N. Engl. J. Med. 356, 567\u2013579 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR192","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1074-7613(01)00218-7","volume":"15","author":"Y Shibata","year":"2001","unstructured":"Shibata, Y. et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15, 557\u2013567 (2001).","journal-title":"Immunity"},{"key":"1815_CR193","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev.physiol.64.090601.113847","volume":"64","author":"BC Trapnell","year":"2002","unstructured":"Trapnell, B. C. & Whitsett, J. A. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu. Rev. Physiol. 64, 775\u2013802 (2002).","journal-title":"Annu. Rev. Physiol."},{"key":"1815_CR194","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2008-05-155689","volume":"113","author":"K Uchida","year":"2009","unstructured":"Uchida, K. et al. Granulocyte\/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 113, 2547\u20132556 (2009).","journal-title":"Blood"},{"key":"1815_CR195","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21011-y","volume":"12","author":"S Sakaue","year":"2021","unstructured":"Sakaue, S. et al. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. Nat. Commun. 12, 1032 (2021).","journal-title":"Nat. Commun."},{"key":"1815_CR196","doi-asserted-by":"publisher","first-page":"e0213179","DOI":"10.1371\/journal.pone.0213179","volume":"14","author":"K Anderson","year":"2019","unstructured":"Anderson, K. et al. Pulmonary alveolar proteinosis: an autoimmune disease lacking an HLA association. PLoS ONE 14, e0213179 (2019).","journal-title":"PLoS ONE"},{"key":"1815_CR197","doi-asserted-by":"publisher","unstructured":"Martin, E. et al. Role of IL-27 in Epstein\u2013Barr virus infection revealed by IL-27RA deficiency. Nature https:\/\/doi.org\/10.1038\/s41586-024-07213-6 (2024).","DOI":"10.1038\/s41586-024-07213-6"},{"key":"1815_CR198","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283\u2013288 (2021).","journal-title":"Nature"},{"key":"1815_CR199","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.abn1034","volume":"383","author":"JR Jaycox","year":"2024","unstructured":"Jaycox, J. R., Dai, Y. & Ring, A. M. Decoding the autoantibody reactome. Science 383, 705\u2013707 (2024).","journal-title":"Science"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-024-01815-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-024-01815-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-024-01815-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T17:07:38Z","timestamp":1714669658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-024-01815-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":199,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1815"],"URL":"https:\/\/doi.org\/10.1038\/s41590-024-01815-y","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.-L.C. declares being an inventor on a patent application PCT\/US2021\/042741, filed on 22 July 2021, submitted by The Rockefeller University, which covers the diagnosis of, susceptibility to and treatment of viral disease and viral vaccines, including COVID-19 and vaccine-associated diseases. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}